glp 1 mash approval Semaglutide Receives FDA for Treatment of Novo Nordisk claims first GLP-1

Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis

Pairing carbohydrates with protein, fiber, or healthy fats may also help improve satiety and stabilize blood sugar after meals

The GLP-1 drug patches containing semaglutide are still in their experimental stage

Starting at lower doses and increasing according to product-specific schedules (ranging from 1-4 weeks depending on the agent) allows physiologic adaptation